Delifului key facts
- Developer of drug-delivery systems intended for pharmaceutical companies.
- Notable investors include Beijing Xietong Chuangxin Holding, Guangdong Academy of Greater Bay Area Studies, Heying Asset Management.
- Status: Privately Held (backing).
- ·Watch Delifului: the Monday email on marks, rounds and moves
Delifului funding rounds
No funding rounds for Delifului are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Delifului investors
3 investors are on record for Delifului, including Beijing Xietong Chuangxin Holding, Guangdong Academy of Greater Bay Area Studies and Heying Asset Management.
About Delifului
Developer of drug-delivery systems intended for pharmaceutical companies. The company's research and development direction is closely centered on clinical pain points, and its research and development pipeline covers a wide range of important indications, including anti-tumor, cardiovascular, cerebrovascular, anti-fungal, and postoperative analgesia, enabling clients' drug delivery processes to improve drug efficacy and reduce toxic side effects.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2010
- Website
- bj-delivery.cn/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Delifului doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.